Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FT538 Monotherapy and with Vorinostat for Persistent Low-Level HIV Viremia
NCT05700630Phase 1Withdrawn
- Sponsor
- Masonic Cancer Center
- Start
- Jul 2024
- Primary completion
- Jul 2024
- Modality
- Gene Editing, Gene Silencing, Patient-derived iPSCs
- Countries
- 1
01
Overview
Phase 1, open-label trial of FT538 in human immunodeficiency virus type 1 infection (HIV-1) (2 arms), sponsored by Masonic Cancer Center. Primary endpoint: Determine the safety and feasibility of administering FT538 monotherapy at 26 months. Planned start Jul 2024; status: withdrawn.
02
Drugs
FT538
03
Conditions
human immunodeficiency virus type 1 infection (HIV-1)
Beyond the preview
Go deeper on NCT05700630.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05700630.